SYRE Q3 2023 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$18M

Net Income

-$40M

EPS (Diluted)

$-9.34

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$207M

Total Liabilities

$453M

Stockholders' Equity

-$245M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$174,000	-100.0%
Gross Profit	$0	-$328,000	+100.0%
Operating Income	-$18M	-$19M	+2.2%
Net Income	-$40M	-$18M	-120.0%